[8-K] Tenax Therapeutics, Inc. Reports Material Event
Tenax Therapeutics has furnished a press release disclosing its financial results for the quarter ended June 30, 2025, attaching that release as Exhibit 99.1 to this Form 8-K. The company also included an interactive XBRL cover page as Exhibit 104 and reconfirmed that the press release is furnished rather than filed, so it is not subject to Section 18 liability and is not incorporated by reference into other filings except by specific reference. The 8-K itself does not include any numerical financial figures; readers must consult the attached press release for detailed results and metrics.
Tenax Therapeutics ha diffuso un comunicato stampa con i risultati finanziari del trimestre chiuso il 30 giugno 2025, allegando tale comunicato come Exhibit 99.1 al presente Form 8‑K. La società ha inoltre incluso una pagina di copertina XBRL interattiva come Exhibit 104 e ha ribadito che il comunicato è stato fornito (furnished) e non depositato (filed); pertanto non è soggetto alla responsabilità ai sensi della Section 18 né viene incorporato per riferimento in altri documenti salvo espressa indicazione. Il Form 8‑K in sé non contiene cifre finanziarie: per i risultati e le metriche dettagliate è necessario consultare il comunicato allegato.
Tenax Therapeutics ha divulgado un comunicado de prensa con los resultados financieros del trimestre cerrado el 30 de junio de 2025, adjuntando ese comunicado como Exhibit 99.1 a este Form 8‑K. La compañía también incluyó una portada XBRL interactiva como Exhibit 104 y recalcó que el comunicado se ha facilitado (furnished) y no presentado (filed), por lo que no está sujeto a responsabilidad conforme a la Section 18 ni se incorpora por referencia en otros documentos salvo que exista una referencia expresa. El 8‑K en sí no contiene cifras financieras; para ver resultados y métricas detalladas hay que consultar el comunicado adjunto.
Tenax Therapeutics는 2025년 6월 30일로 종료된 분기 실적을 공개하는 보도자료를 제공하고, 해당 보도자료를 이 Form 8‑K의 Exhibit 99.1로 첨부했습니다. 회사는 또한 대화형 XBRL 표지 페이지를 Exhibit 104로 포함했으며, 보도자료가 제출된(furnished) 것이지 공식 제출(filed)이 아님을 재확인하여 해당 자료는 Section 18에 따른 책임의 대상이 아니며 명시적 참조가 있는 경우를 제외하고 다른 제출서류에 의해 참조로 통합되지 않는다고 밝혔습니다. 이 8‑K 자체에는 수치상의 재무 데이터가 포함되어 있지 않으므로 상세한 결과와 지표는 첨부된 보도자료를 참조해야 합니다.
Tenax Therapeutics a diffusé un communiqué de presse présentant ses résultats financiers pour le trimestre clos le 30 juin 2025, en joignant ce communiqué en tant que Exhibit 99.1 à ce Form 8‑K. La société a également inclus une page de couverture XBRL interactive en tant que Exhibit 104 et a reconfirmé que le communiqué est fourni (furnished) et non déposé (filed), de sorte qu’il n’est pas soumis à la responsabilité en vertu de la Section 18 et qu’il n’est pas incorporé par référence dans d’autres documents sauf mention expresse. Le 8‑K lui‑même ne contient aucun chiffre financier ; les lecteurs doivent consulter le communiqué joint pour les résultats détaillés et les indicateurs.
Tenax Therapeutics hat eine Pressemitteilung zu den Finanzergebnissen für das Quartal zum 30. Juni 2025 veröffentlicht und diese Mitteilung als Exhibit 99.1 zu diesem Form 8‑K beigefügt. Das Unternehmen hat außerdem eine interaktive XBRL-Titelseite als Exhibit 104 aufgenommen und bestätigt, dass die Pressemitteilung „furnished“ und nicht „filed“ ist; sie unterliegt daher nicht der Haftung nach Section 18 und wird nur bei ausdrücklicher Nennung in andere Einreichungen durch Bezugnahme aufgenommen. Das 8‑K selbst enthält keine finanziellen Zahlen; ausführliche Ergebnisse und Kennzahlen sind der beigefügten Pressemitteilung zu entnehmen.
- Disclosure of results via an attached press release (Exhibit 99.1) for the quarter ended June 30, 2025.
- Interactive data included through Exhibit 104 (Cover Page Interactive Data File), supporting data accessibility.
- No financial figures are included in the 8-K; the filing does not present revenue, earnings, or other metrics.
- The press release is explicitly furnished, not filed, limiting Section 18 liability and not being automatically incorporated by reference into other filings.
Insights
TL;DR: Routine earnings disclosure furnished as an exhibit; the 8-K contains no financial figures, so the filing alone does not reveal material results.
The filing confirms Tenax furnished a press release reporting second-quarter results for the period ended June 30, 2025 and attached it as Exhibit 99.1. Because the company states the release is "furnished, not filed," the 8-K does not itself present numeric results or Section 18 filing status protections. From an analyst perspective, the exhibit likely contains the substantive metrics; the 8-K is a procedural notice rather than a source of underlying financial detail.
TL;DR: Disclosure was furnished, not filed, which limits Section 18 liability; the 8-K documents the release but provides no financial data within the filing.
The company explicitly attached a press release as Exhibit 99.1 and an interactive XBRL cover page as Exhibit 104. The 8-K reiterates that the release is furnished and not "filed" for Section 18 purposes and will not be incorporated by reference absent explicit mention in a future filing. This is a routine governance disclosure that clarifies legal treatment of the release but does not convey the substance of the reported results within the 8-K itself.
Tenax Therapeutics ha diffuso un comunicato stampa con i risultati finanziari del trimestre chiuso il 30 giugno 2025, allegando tale comunicato come Exhibit 99.1 al presente Form 8‑K. La società ha inoltre incluso una pagina di copertina XBRL interattiva come Exhibit 104 e ha ribadito che il comunicato è stato fornito (furnished) e non depositato (filed); pertanto non è soggetto alla responsabilità ai sensi della Section 18 né viene incorporato per riferimento in altri documenti salvo espressa indicazione. Il Form 8‑K in sé non contiene cifre finanziarie: per i risultati e le metriche dettagliate è necessario consultare il comunicato allegato.
Tenax Therapeutics ha divulgado un comunicado de prensa con los resultados financieros del trimestre cerrado el 30 de junio de 2025, adjuntando ese comunicado como Exhibit 99.1 a este Form 8‑K. La compañía también incluyó una portada XBRL interactiva como Exhibit 104 y recalcó que el comunicado se ha facilitado (furnished) y no presentado (filed), por lo que no está sujeto a responsabilidad conforme a la Section 18 ni se incorpora por referencia en otros documentos salvo que exista una referencia expresa. El 8‑K en sí no contiene cifras financieras; para ver resultados y métricas detalladas hay que consultar el comunicado adjunto.
Tenax Therapeutics는 2025년 6월 30일로 종료된 분기 실적을 공개하는 보도자료를 제공하고, 해당 보도자료를 이 Form 8‑K의 Exhibit 99.1로 첨부했습니다. 회사는 또한 대화형 XBRL 표지 페이지를 Exhibit 104로 포함했으며, 보도자료가 제출된(furnished) 것이지 공식 제출(filed)이 아님을 재확인하여 해당 자료는 Section 18에 따른 책임의 대상이 아니며 명시적 참조가 있는 경우를 제외하고 다른 제출서류에 의해 참조로 통합되지 않는다고 밝혔습니다. 이 8‑K 자체에는 수치상의 재무 데이터가 포함되어 있지 않으므로 상세한 결과와 지표는 첨부된 보도자료를 참조해야 합니다.
Tenax Therapeutics a diffusé un communiqué de presse présentant ses résultats financiers pour le trimestre clos le 30 juin 2025, en joignant ce communiqué en tant que Exhibit 99.1 à ce Form 8‑K. La société a également inclus une page de couverture XBRL interactive en tant que Exhibit 104 et a reconfirmé que le communiqué est fourni (furnished) et non déposé (filed), de sorte qu’il n’est pas soumis à la responsabilité en vertu de la Section 18 et qu’il n’est pas incorporé par référence dans d’autres documents sauf mention expresse. Le 8‑K lui‑même ne contient aucun chiffre financier ; les lecteurs doivent consulter le communiqué joint pour les résultats détaillés et les indicateurs.
Tenax Therapeutics hat eine Pressemitteilung zu den Finanzergebnissen für das Quartal zum 30. Juni 2025 veröffentlicht und diese Mitteilung als Exhibit 99.1 zu diesem Form 8‑K beigefügt. Das Unternehmen hat außerdem eine interaktive XBRL-Titelseite als Exhibit 104 aufgenommen und bestätigt, dass die Pressemitteilung „furnished“ und nicht „filed“ ist; sie unterliegt daher nicht der Haftung nach Section 18 und wird nur bei ausdrücklicher Nennung in andere Einreichungen durch Bezugnahme aufgenommen. Das 8‑K selbst enthält keine finanziellen Zahlen; ausführliche Ergebnisse und Kennzahlen sind der beigefügten Pressemitteilung zu entnehmen.
FAQ
What did Tenax (TENX) disclose in this Form 8-K?
Where can I find Tenax's Q2 2025 financial results?
Is the press release in the 8-K considered 'filed' with the SEC?
Which exhibits were included with Tenax's 8-K?
What is Tenax's ticker and exchange?
